Hematology and Oncology Principles

Hematology and oncology reward a small number of high-yield frameworks rather than brute memorization. If you can classify an anemia by cell size, reason through the two arms of hemostasis, and separate an oncogene from a tumor suppressor, you can predict most Step 1 vignettes in this domain. The sections below build those frameworks conceptually.

Core Idea

• Classify anemias by mean corpuscular volume (MCV) first — microcytic, normocytic, or macrocytic narrows the differential before any other clue.
• Hemostasis has two arms: primary (platelets and von Willebrand factor forming the initial plug) and secondary (the coagulation cascade laying down fibrin).
• Cancer is a disease of unregulated growth driven by activated oncogenes and inactivated tumor suppressors, acquiring the hallmark capabilities that allow invasion and metastasis.

Red Cell Indices and the Anemias

The MCV measures average red cell size and is the anchor for classification.

• Microcytic (low MCV): think of problems making hemoglobin — iron deficiency, chronic disease (iron is sequestered), thalassemia (globin chain defect), and lead poisoning or sideroblastic states. The classic pattern is small, pale (hypochromic) cells.
• Normocytic (normal MCV): split by the reticulocyte count. A high reticulocyte response points to hemolysis or acute blood loss; a low response points to marrow underproduction (aplastic states, chronic disease, renal failure with low erythropoietin).
• Macrocytic (high MCV): megaloblastic causes reflect impaired DNA synthesis — vitamin B12 or folate deficiency; nonmegaloblastic causes include liver disease and alcohol. B12 deficiency uniquely adds neurologic signs.

Red cell distribution width (RDW) flags variability in size and helps separate look-alikes, such as iron deficiency (high RDW) from thalassemia trait (often normal RDW).

Hemostasis: Primary and Secondary

Primary hemostasis forms the initial platelet plug. Platelets adhere to exposed collagen via von Willebrand factor, then activate and aggregate. Defects here cause mucocutaneous bleeding — nosebleeds, gum bleeding, petechiae, heavy menses. Think platelet-count problems and von Willebrand disease.

Secondary hemostasis stabilizes the plug with fibrin through the coagulation cascade:

• Intrinsic pathway is assessed by the PTT (partial thromboplastin time) and involves factors such as VIII, IX, XI, XII.
• Extrinsic pathway is assessed by the PT (prothrombin time) and centers on factor VII (the shortest-lived factor).
• Both converge on the common pathway (factors X, V, II/thrombin, fibrinogen).

A useful mnemonic: PT = extrinsic and warfarin/factor VII; PTT = intrinsic and heparin. Deep bleeding into joints and muscles suggests a coagulation factor defect (for example, hemophilia).

Bleeding vs. Clotting Disorders

• Bleeding disorders arise from too few or dysfunctional platelets, deficient clotting factors, or deficient von Willebrand factor. Pattern recognition (mucocutaneous vs. deep tissue) plus PT/PTT localizes the lesion.
• Clotting (thrombotic) disorders reflect Virchow's triad: endothelial injury, stasis, and hypercoagulability. Inherited hypercoagulable states tip the balance toward pathologic clot formation.

Blood Cell Lineages

All blood cells arise from a hematopoietic stem cell, which branches into:

• Myeloid lineage: red cells, platelets (from megakaryocytes), granulocytes (neutrophils, eosinophils, basophils), and monocytes/macrophages.
• Lymphoid lineage: B cells, T cells, and natural killer cells.

Knowing lineage explains cytopenias and leukemia classification.

Oncology Principles

• Oncogenes are gain-of-function drivers; a mutation in a single copy is enough to promote growth (dominant at the cellular level). Tumor suppressors are loss-of-function brakes, typically requiring two hits (both alleles lost) per Knudson's hypothesis.
• Hallmarks of cancer include sustained proliferative signaling, evading growth suppressors, resisting apoptosis, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.
• Grade describes how abnormal the cells look (differentiation) under the microscope; stage describes how far the tumor has spread (size, nodes, metastases). Stage generally predicts prognosis better than grade.
• Tumor markers are substances measured to monitor treatment response or recurrence, not primarily to screen or diagnose in isolation.
• Metastasis proceeds through invasion of local tissue, entry into vessels (intravasation), survival in circulation, exit at a distant site (extravasation), and colonization — often favoring specific organs.

High-Yield Exam Patterns

• A vignette leading with MCV wants you to classify the anemia before reading further.
• Normocytic anemia + reticulocyte count is a two-step branch: high = destruction/loss, low = underproduction.
• Mucocutaneous bleeding = primary hemostasis; deep joint/muscle bleeding = secondary hemostasis.
• Isolated prolonged PTT points to the intrinsic pathway; isolated prolonged PT to the extrinsic pathway.
• Distinguish oncogene (one hit, dominant) from tumor suppressor (two hits, recessive) in genetics stems.
• When asked what best predicts prognosis, favor stage over grade.

Common Traps to Avoid

• Confusing PT with the intrinsic pathway — PT tracks the extrinsic/factor VII arm.
• Assuming every macrocytic anemia is megaloblastic — liver disease and alcohol cause nonmegaloblastic macrocytosis.
• Mixing up grade and stage; they answer different questions.
• Calling a tumor suppressor mutation dominant — it usually requires loss of both alleles.
• Forgetting that chronic disease anemia can be microcytic or normocytic depending on severity.